Prasad’s departure could mark turning point for FDA

The departure of Vinay Prasad, one of the most controversial figures in recent FDA history, may mark a turning point for the agency and for the Trump administration’s approach to regulating drug development.

The combination of new oversight structures within HHS, leadership changes at FDA, and the search for a new CBER director show how the administration is seeking to stabilize the agency while maintaining political influence over key regulatory decisions. The White House is trying to quell controversies over vaccines and orphan drug regulation, while keeping high-profile leaders in place. ...